CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 13 enrolled
Drug / intervention
Psilocybindrug
Likely dose
Psilocybin 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02971605
NCT02971605Phase 2Completed
CompareCT.gov

Measurement of Persisting Changes in Emotional Brain Functioning Produced by Psilocybin

Johns Hopkins University·interventional·Posted Nov 23, 2016·Updated Sep 10, 2019

In Brief

A Phase 2 clinical trial evaluating Psilocybin for Healthy. Completed, enrolled 13 participants across 1 site.

Detailed Summary

The proposed pilot study will assess whether ingestion of a classic hallucinogen (psilocybin) leads to changes in emotion processing and neural circuitry that may predict repeated self-administration of this drug and underlie an atypical mechanism of abuse liability, which may vitally contribute to the understanding of the potential for abuse and the underlying mechanisms supporting abuse of classic hallucinogens.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 23, 2016
Enrollment StartJul 1, 2017
Primary CompletionAug 21, 2018
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 9.6 years ago

Interventions

Psilocybindrug

25 mg/70 kg Psilocybin